John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Curr Opin Neurol. 2023 Oct 1;36(5):450-454. doi: 10.1097/WCO.0000000000001191. Epub 2023 Aug 21.
The purpose of this review is to summarise the recent developments in trial readiness, natural history studies, and interventional clinical trials for Becker muscular dystrophy (BMD).
As several treatment concepts have claimed to convert patients with Duchenne muscular dystrophy (DMD) into a BMD phenotype, BMD itself has moved into the focus of clinical research. Natural history studies have helped to better characterize patients with BMD and the disease is now a target for interventional trials. In parallel, there have been advances in diagnostics and in the development of preclinical models.
Despite increased collaborative efforts to improve trial readiness amongst patients with BMD, there is still a lack of long-term natural history data, and the broad spectrum of disease severity remains a challenge for well designed clinical trials.
本综述旨在总结贝克肌营养不良症(BMD)在试验准备、自然病史研究和介入临床试验方面的最新进展。
由于几种治疗方案声称可以将杜氏肌营养不良症(DMD)患者转化为 BMD 表型,因此 BMD 本身已成为临床研究的焦点。自然病史研究有助于更好地描述 BMD 患者的情况,现在该病已成为介入临床试验的目标。与此同时,诊断技术和临床前模型的开发也取得了进展。
尽管为提高 BMD 患者的试验准备工作进行了更多的合作努力,但仍缺乏长期自然病史数据,疾病的广泛严重程度仍是精心设计临床试验的挑战。